MDGL
Madrigal Pharmaceuticals Inc.
$475.70
-$14.04(-2.87%)
50
Overall
40
Value
58
Tech
52
Quality
Market Cap
$11.36B
Volume
233.34K
52W Range
$265.00 - $615.00
Target Price
$649.38
Company Overview
| Mkt Cap | $11.36B | Price | $475.70 |
| Volume | 233.34K | Change | -2.87% |
| P/E Ratio | -24.4 | Open | $486.17 |
| Revenue | $180.1M | Prev Close | $489.73 |
| Net Income | $-465.9M | 52W Range | $265.00 - $615.00 |
| Div Yield | N/A | Target | $649.38 |
| Overall | 50 | Value | 40 |
| Quality | 52 | Technical | 58 |
No chart data available
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche
TipRanks Auto-Generated Newsdesk•4 days ago
Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
TipRanks Weekend Auto-Generated Newsdesk•10 days ago
Madrigal Pharmaceuticals (MDGL) Gets a Hold from Bank of America Securities
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDGL | $475.70 | -2.9% | 233.34K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Madrigal Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW